MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

MDT

96.67

+0.59%↑

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

+0.18%↑

Inicio・Lista de Acciones・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Cerrado

SectorSanidad

43.84 -1.04

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

43.27

Máximo

44.3

Métricas clave
By Trading Economics
Ingresos	-6.2M -91M
Margen de beneficios	-867.293
Empleados	316
EBITDA	4M -90M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+22.57% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	196M 3.4B
Apertura anterior	44.88
Cierre anterior	43.84

Noticias sobre sentimiento de mercado

By Acuity

50%

149 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

34.81 / 38.24 Soporte y Resistencia

Xenon Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

30 dic 2025, 23:49 UTC

Adquisiciones, fusiones, absorciones

WiseTech to Sell Expedient to Appease Competition Regulator

30 dic 2025, 17:12 UTC

Principales Movimientos del Mercado

CapsoVision Shares Rise on FDA Application for AI Tool in Swallowable Camera

30 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

30 dic 2025, 21:16 UTC

Adquisiciones, fusiones, absorciones

Penguin Solutions: Smart Modular to Sell Zilia Stake for $46M

30 dic 2025, 21:08 UTC

Charlas de Mercado

U.S. Natural Gas Futures Take Another Wild Ride -- Market Talk

30 dic 2025, 20:41 UTC

Charlas de Mercado

Oil Futures Settle Lower in Sluggish Trade -- Market Talk

30 dic 2025, 20:37 UTC

Ganancias

The 5 Best Names to Play AI in 2026, According to Wall Street's Loudest Tech Bull -- Barrons.com

30 dic 2025, 19:29 UTC

Charlas de Mercado

Corn Extends Pullback in Light Trade -- Market Talk

30 dic 2025, 18:29 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By Three to 412 -- Market Talk

30 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

30 dic 2025, 16:20 UTC

Ganancias

Boeing Stock Is on a Roll. Why It Could Gain 25% in the Next Year. -- Barrons.com

30 dic 2025, 16:18 UTC

Adquisiciones, fusiones, absorciones

Meta Buys AI Startup Manus, Adding Millions of Paying Users -- 2nd Update

30 dic 2025, 16:10 UTC

Charlas de Mercado

Eurozone Government Bond Yields Rise, Euro Falls Ahead of Fed Minutes -- Market Talk

30 dic 2025, 15:24 UTC

Charlas de Mercado

Australian Dollar Could Rise Versus Sterling -- Market Talk

30 dic 2025, 15:10 UTC

Adquisiciones, fusiones, absorciones

Meta Stock Rises After Buying Manus. What the China-Founded AI Start-Up Brings. -- Barrons.com

30 dic 2025, 14:24 UTC

Adquisiciones, fusiones, absorciones

LVMH: The Three Publications Are Challenges, Sciences & Avenir, and La Recherche

30 dic 2025, 14:22 UTC

Adquisiciones, fusiones, absorciones

LVMH : Szafran Will Serve as Publishing Director For all Three Publications

30 dic 2025, 14:20 UTC

Adquisiciones, fusiones, absorciones

LVMH: As Part of the Deal, Maurice Szafran Has Been Named President of Les Editions Croque Futur

30 dic 2025, 14:17 UTC

Adquisiciones, fusiones, absorciones

LVMH: The Deal Also Reflects LVMH's Commitment to Support High-Quality Information and Scientific Culture

30 dic 2025, 14:16 UTC

Adquisiciones, fusiones, absorciones

LVMH: The Deal Aims to Accelerate the Development and Distribution of the Publications Mainly in Digital Format

30 dic 2025, 14:14 UTC

Adquisiciones, fusiones, absorciones

LVMH: The Move Includes Three Publications Into UFIPAR Investment Company

30 dic 2025, 14:12 UTC

Adquisiciones, fusiones, absorciones

LVMH: Les Editions Croque Futur Is a French Publishing House

30 dic 2025, 14:10 UTC

Adquisiciones, fusiones, absorciones

LVMH Acquires Les Editions Croque Futur

30 dic 2025, 13:49 UTC

Adquisiciones, fusiones, absorciones

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

30 dic 2025, 13:36 UTC

Charlas de Mercado

U.S. Natural Gas Continues Weather-Driven Rally -- Market Talk

30 dic 2025, 13:30 UTC

Charlas de Mercado

Crude Futures Gain in Light Holiday Trade -- Market Talk

30 dic 2025, 12:55 UTC

Charlas de Mercado

Triple Flag Precious Metals Offers Opportunity While Mitigating Risk -- Market Talk

30 dic 2025, 11:55 UTC

Charlas de Mercado

Ganancias

Investors Await Tesco's Profit Outlook Following U.K. Budget Reforms -- Market Talk

30 dic 2025, 11:47 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Meta's Manus Deal Is a Taster of AI Trends for 2026. Watch This Risk. -- Barrons.com

30 dic 2025, 11:35 UTC

Adquisiciones, fusiones, absorciones

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

Comparación entre iguales

Cambio de precio

Xenon Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

22.57% repunte

Estimación a 12 Meses

Media 54.96 USD 22.57%

Máximo 65 USD

Mínimo 44 USD

De acuerdo con 15 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Xenon Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

15 ratings

Comprar

Mantener

Vender

De acuerdo con 15 analistas que ofrecen calificaciones bursátiles a para Xenon Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

34.81 / 38.24Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

149 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.